| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/11/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/11/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/11/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/04/2023 |
4
| Stephan Dietrich A (Founder and CEO) has filed a Form 4 on NeuBase Therapeutics, Inc.|
Txns:
| Exercised 93,234 options to buy
@ $0.022, valued at
$2.1k
|
|
| 08/03/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits &nbs... |
| 08/01/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 07/07/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 06/30/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Form of Series A Common Stock Purchase Warrant",
"Form of Series B Common Stock Purchase Warrant",
"Form of Pre-Funded Common Stock Purchase Warrant (Registered Direct Offering)",
"Form of Pre-Funded Common Stock Purchase Warrant (PIPE Private Placement)",
"Form of Placement Agent Common Stock Purchase Warrant",
"Opinion of Paul Hastings LLP",
"Securities Purchase Agreement, (Registered Direct Offering)",
"Securities Purchase Agreement, (PIPE Private Placement)",
"Registration Rights Agreement",
"NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules" |
|
| 06/30/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/30/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/18/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/24/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/17/2023 |
4
| Branning Todd P. (CFO) has filed a Form 4 on NeuBase Therapeutics, Inc.|
Txns:
| Granted 54,200 shares
@ $0 |
|
| 03/17/2023 |
4
| Stephan Dietrich A (CEO and Director) has filed a Form 4 on NeuBase Therapeutics, Inc.|
Txns:
| Granted 153,000 shares
@ $0 |
|
| 03/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/14/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 01/27/2023 |
SC 13G/A
| Kershner Trading Americas,LLC reports a 4.5% stake in NeuBase Therapeutics, Inc. |
| 12/29/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/29/2022 |
8-K
| Quarterly results |
| 12/21/2022 |
8-K
| Quarterly results |
| 12/21/2022 |
10-K
| Annual Report for the period ended September 30, 2022 |
| 11/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/24/2022 |
8-K
| Quarterly results |
| 10/14/2022 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 10/03/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
|